A retrospective cohort study found that cancer patients receiving vancomycin combined with piperacillin-tazobactam faced a fourfold higher risk of acute kidney injury compared with vancomycin alone. The evidence strengthens concerns around antibiotic regimen selection in medically complex oncology populations. For stewardship and pharmacy, the study supports more aggressive risk stratification—especially for patients with baseline renal vulnerabilities or competing nephrotoxin exposures. Industry relevance also extends to protocol design: teams may need to align empirical therapy pathways and monitoring schedules to minimize avoidable AKI while preserving antimicrobial efficacy.